| Literature DB >> 18316258 |
Jean-Yves Reginster, Julien Collette, Audrey Neuprez, Brigitte Zegels, Rita Deroisy, Olivier Bruyere.
Abstract
Most of the currently available anti-osteoporosis medications promptly and significantly influence the rate of bone turnover. Biochemical markers of bone turnover now provide a high sensitivity to change, allowing the detection of these bone turnover changes within a couple of weeks. Since the anti-fracture efficacy of inhibitors of bone resorption or stimulators of bone formation appears to be largely independent of baseline bone turnover, biochemical markers do not appear to play a significant role in the selection of one particular drug, for an individual patient. However, there are consistent data showing that short-term changes in biochemical markers of bone turnover may be significant predictors of future changes in bone mineral density or fracture reduction, hence suggesting that bone turnover markers play a significant role in the monitoring of anti-osteoporosis therapy.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18316258 DOI： 10.1016/j.bone.2008.01.021
Source DB: PubMed Journal: Bone ISSN： 1873-2763 Impact factor: 4.398